

Efficacy of cabazitaxel in patients with HER2-negative metastatic breast cancer

Submission date 06/02/2013	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 20/06/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 17/03/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/trials/A-trial-looking-at-cabazitaxel-for-HER-2-negative-breast-cancer-that-has-spread-to-the-brain>

Contact information

Type(s)

Scientific

Contact name

Dr Zafar Malik

Contact details

The Clatterbridge Cancer Centre NHS Foundation Trust
Clatterbridge Road
Bebington
Wirral
United Kingdom
CH63 4JY

Type(s)

Public

Contact name

Ms Helen Scott

Contact details

Cancer Research UK Liverpool Cancer Trials Unit
Block C, Waterhouse Building
1-3 Brownlow Street
Liverpool
United Kingdom

L69 3GL
+44 (0)151 794 8209
hscott@liv.ac.uk

Additional identifiers

EudraCT/CTIS number
2012-000542-35

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
RDD490

Study information

Scientific Title

Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases (CiPHER)

Acronym

CiPHER

Study objectives

Cabazitaxel is an effective cytotoxic agent that crosses the blood brain barrier and we hope to investigate this attribute in this Phase II study across several UK recruitment centres. Potentially this therapy could afford survival advantage. The primary aim of this study is to assess the feasibility of Cabazitaxel use in breast cancer with brain metastases by determining whether there is evidence for Cabazitaxel increasing 18 week survival from 67% to 81%.

The study will require a maximum of 62 patients. The trial would be terminated for futility if 21 or fewer patients out of the first 31 survive to 18 weeks. Otherwise, the remaining 31 patients will be recruited (unless advised to the contrary by the DMC) and the null hypothesis will be rejected if there are more than 47 survivors at 18 weeks out of the 62 patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee North West Liverpool Central, 22/05/2013, REC ref: 13/NW/0153

Study design

Single-arm Phase II study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases.

Interventions

Patients on this study will receive cabazitaxel chemotherapy treatment and palliative radiotherapy will be deferred until evidence of disease progression. These patients will be monitored clinically and radiologically every three and six weeks respectively. Cabazitaxel 25 mg /m² given on day 1 of each treatment cycle, intravenously, for one hour every 21 days. Diagnostic biopsy of primary tissue, urine samples (baseline and end of treatment) and blood samples (baseline, day 1 of each cycle and at end of treatment) will be collected, processed and stored for future research purposes. This will be with the aim of identifying serum and urinary biomarkers of predictive and prognostic significance. Baseline diagnostic tissues will be used for gene expression profiling and linked with serum and urinary biomarkers and proteomic profiles to identify markers of efficacy, resistance and toxicity.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Cabazitaxel

Primary outcome measure

Overall proportion surviving at 18 weeks from registration

Secondary outcome measures

1. Progression-free survival (PFS) defined as the time from registration to the first of one of the following: development of disease progression or death from any cause
2. Overall response for extracranial visceral metastases (ORv) as defined in RECIST 1.0 , recorded from the start of treatment to 18 weeks
3. Overall response for CNS lesions (ORc) defined as a best response of at least PR, recorded from the start of treatment to 18 weeks
4. Acute toxicity (CTCAE v4) after each treatment cycle up to 18 weeks (for the purposes of safety, toxicity will be assessed up until 28 days after the last dose of study treatment)
5. Time to radiotherapy (measured from treatment start date until commencement of radiotherapy)
6. Time to neurological deterioration

Overall study start date

01/03/2012

Completion date

25/07/2018

Eligibility

Key inclusion criteria

First or second line metastatic HER2 negative* breast cancer

1. Oligometastatic brain disease that is unsuitable for surgical resection and/or stereotactic radiosurgery
2. Age 18 years or over
3. ECOG performance status 0-2
4. Diagnosis of metastatic HER2-negative breast cancer
5. At least one measurable target lesion (RECIST 1.0) in the brain** (unsuitable for resection) identified by CT scan or MRI within 21 days of registration.
6. Females of child bearing potential who have a negative pregnancy test prior to study entry
7. Agree to use adequate contraception which they agree to continue for 12 months after the study treatment
8. Ability and capacity to comply with study and follow-up procedure
9. Able to provide written informed consent

*Patients with ER+ve or ER-ve disease are eligible for the study

** Patients with meningeal disease are eligible provided they fit the other criteria. Extracranial disease is not a requirement of this study.

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

62

Total final enrolment

19

Key exclusion criteria

1. Received prior radiotherapy/radiosurgery to the brain (radiotherapy may be offered on disease progression)
2. Received >2 lines of chemotherapy for metastatic recurrent disease (adjuvant treatment is permitted) prior to registration

3. Received any chemotherapy after the diagnosis of brain metastases
4. Previous hormone therapy if it will not be discontinued before Cabazitaxel treatment
5. Patients who have received an increasing dose of steroids to control CNS symptoms within 14 days of registration (steroid use is permitted only when patient is stable at a specific dose at the time of screening)
6. Visceral metastases with no recorded brain metastases
7. Pregnancy or lactation
8. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 28 days prior to registration
9. Patients with a history of other previous malignancy except treated CIN or non melanomatous skin cancer
10. Grade ≥ 2 peripheral motor and/or sensory neuropathy
11. Grade ≥ 2 mucositis oral
12. History of severe hypersensitivity reaction (\geq grade 3) to taxanes
13. History of severe hypersensitivity reaction (\geq grade 3) to polysorbate 80-containing drugs
14. Other concurrent serious illness or medical conditions which make it undesirable for the patient to enter the trial (including uncontrolled diabetes mellitus)
15. Inadequate organ and bone marrow function as evidenced by:
 - 15.1. Haemoglobin < 9.0 g/dL
 - 15.2. Absolute neutrophil count $< 1.5 \times 10^9/L$
 - 15.3. Platelet count $< 100 \times 10^9/L$
 - 15.4. AST/SGOT and/or ALT/SGPT $> 2.5 \times ULN$
 - 15.5. total bilirubin $> 1.0 \times ULN$
 - 15.6. Serum creatinine $> 1.5 \times ULN$. If creatinine $1.0 - 1.5 \times ULN$, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance < 60 mL/min should be excluded
16. Active infection requiring systemic antibiotic or anti fungal medication.
17. Participation in another clinical trial with any investigational drug within 30 days prior to registration
18. Administration of potent inhibitors and inducers of P450 3A4/5 enzymes within 7 days of registration, or planned concurrent administration whilst on study. This excludes steroid treatment which is standard care treatment for patients with brain metastases
19. Concomitant vaccination with live attenuated vaccines

Date of first enrolment

01/03/2012

Date of final enrolment

05/12/2017

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

The Clatterbridge Cancer Centre NHS Foundation Trust
Wirral
United Kingdom
CH63 4JY

Sponsor information

Organisation

The Clatterbridge Cancer Centre NHS Foundation Trust (UK)

Sponsor details

Clatterbridge Road
Bebington
Wirral
England
United Kingdom
CH63 4JY

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/05gcq4j10>

Funder(s)

Funder type

Industry

Funder Name

Sanofi: CABAZ_L_5958

Alternative Name(s)

sanofi-aventis, Sanofi US, Sanofi-Aventis U.S. LLC, Sanofi U.S.

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

31/03/2020

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results			28/05/2020	No	No
Plain English results			17/03/2021	No	Yes
HRA research summary			28/06/2023	No	No